01—Abstract
Summary
Summary of the 8-K filed February 12, 2026. Cited figures are marked; the original filing is the authoritative source.
BridgeBio Pharma, Inc. (Nasdaq: BBIO) reported positive topline results from PROPEL 3, its global Phase 3 pivotal study of oral infigratinib in children with achondroplasia.
The one-year, 2:1 randomized, double-blinded, placebo-controlled study met its primary endpoint, change from baseline in annualized height velocity (AHV) at Week 52 (p<0.0001), with an LS mean treatment difference of +1.74 cm/year versus placebo (mean treatment difference of +2.10 cm/year). The absolute AHV in the infigratinib arm was 5.96 cm/year versus 4.22 cm/year on placebo. The company also met its key secondary endpoint, change from baseline in height Z-score at Week 52 (p<0.0001), with an LS mean treatment difference of +0.32 SD and an LS mean increase of +0.41 SD on the treatment arm.
In a pre-specified exploratory analysis of children younger than 8 years old (more than 50%a of participants), infigratinib showed a statistically significant improvement in body proportionality against placebo, with an LS mean treatment difference of -0.05 (p<0.05). In the overall population, the treatment difference was -0.02 versus placebo (p=0.1849). The company reported that infigratinib was well tolerated, with no discontinuations or serious adverse events related to study drug.
Three cases (4%b) of hyperphosphatemia were reported, all mild and transient, and none required dose reduction or discontinuation. BridgeBio intends to meet with regulators to discuss New Drug Application (NDA) and Marketing Authorization Application (MAA) submissions for achondroplasia in the second half of 2026. The company also plans to accelerate development of infigratinib in hypochondroplasia and is enrolling the observational run-in for its Phase 3 trial in that indication.
Infigratinib holds FDA Breakthrough Therapy Designation for achondroplasia, which the company describes as the only therapeutic option in development for achondroplasia with that designation. The company also referenced Orphan Drug, Fast Track, and Rare Pediatric Disease designations.
02—Key points
Key Highlights
- PROPEL 3 met its primary endpoint: change from baseline in AHV at Week 52 was superior to placebo, with an LS mean treatment difference of +1.74 cm/year (p<0.0001).
- The key secondary endpoint, change from baseline in height Z-score at Week 52, was met (p<0.0001), with an LS mean treatment difference of +0.32 SD and an LS mean increase of +0.41 SD on the treatment arm.
- Absolute AHV at Week 52 was 5.96 cm/year on infigratinib versus 4.22 cm/year on placebo.
- In a pre-specified exploratory analysis of children younger than 8 years old (more than 50% of participants), infigratinib showed a statistically significant improvement in body proportionality against placebo (LS mean treatment difference of -0.05, p<0.05).
- The safety profile was described as well tolerated, with no discontinuations or serious adverse events related to study drug and three cases (4%) of mild, transient hyperphosphatemia.
- BridgeBio plans NDA and MAA submissions for achondroplasia in the second half of 2026 and intends to accelerate development in hypochondroplasia.
- Infigratinib has FDA Breakthrough Therapy Designation for achondroplasia and is described as the only oral therapy designed to target FGFR3 in development for the condition.
03—Questions
Frequently Asked Questions
What were the primary results of the PROPEL 3 study?
The study met its primary endpoint, with change from baseline in annualized height velocity at Week 52 superior to placebo. The LS mean treatment difference was +1.74 cm/year (p<0.0001), and the mean treatment difference was +2.10 cm/year.
Did the study meet its secondary endpoints?
The key secondary endpoint, change from baseline in height Z-score (achondroplasia reference population) at Week 52, was met (p<0.0001). The LS mean treatment difference was +0.32 SD, and the LS mean change on the treatment arm was +0.41 SD. Absolute AHV at Week 52 was also significantly improved, at 5.96 cm/year versus 4.22 cm/year on placebo.
What did the study show about body proportionality?
In a pre-specified exploratory analysis of children younger than 8 years old (more than 50% of participants), infigratinib achieved a statistically significant improvement against placebo, with an LS mean treatment difference of -0.05 (p<0.05). In the overall population, the LS mean treatment difference was -0.02 versus placebo (p=0.1849). The company describes this as an exploratory analysis.
What is the safety profile of oral infigratinib?
The company reported no discontinuations related to study drug and no serious adverse events related to study drug. There were three cases (4%) of hyperphosphatemia, all mild, transient, and asymptomatic, none requiring dose reduction or discontinuation. No adverse events associated with FGFR1 or FGFR2 inhibition, such as retinal or corneal events, were reported.
What are the next regulatory and development steps?
BridgeBio intends to meet with regulatory authorities to discuss NDA and MAA submissions for achondroplasia in the second half of 2026. The company also plans to accelerate development in hypochondroplasia, where it is enrolling the observational run-in for the Phase 3 trial, and continues the PROPEL Infant & Toddler trial in younger age groups.
04—Continue